Steven O'Day - Jun 11, 2024 Form 4 Insider Report for AGENUS INC (AGEN)

Role: Chief Medical Officer
Signature: /s/Christine Klaskin, as attorney-in-fact for Steven O'Day
Stock symbol: AGEN
Transactions as of: Jun 11, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/18/2024, 04:05 PM
Previous filing: Jan 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGEN	Stock Option	Award	$0	+37.9K		$0.00	37.9K	Jun 11, 2024	Common Stock	37.9K	$12.26	Direct	F1
transaction	AGEN	Stock Option	Award	$0	+10K		$0.00	10K	Jun 11, 2024	Common Stock	10K	$12.26	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. These options vest as to 50% of the underlying shares on June 27, 2024 and 50% of the underlying shares on September 27, 2024. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 758,140 Stock Options with an exercise price of $0.61.
F2	Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 200,000 Stock Options with an exercise price of $0.61.

Content

Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. These options vest as to 50% of the underlying shares on June 27, 2024 and 50% of the underlying shares on September 27, 2024. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 758,140 Stock Options with an exercise price of $0.61.

Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 200,000 Stock Options with an exercise price of $0.61.